Literature DB >> 21172273

Pulmonary Crohn's disease: A rare extra-intestinal manifestation treated with infliximab.

Natalia Pedersen1, Dana Duricova, Pia Munkholm.   

Abstract

Crohn's disease is a chronic inflammatory bowel disease often presenting with extra-intestinal manifestations. However, pulmonary involvement is quite rare. We report a case of Crohn's disease with pulmonary extra-intestinal manifestation (bronchiolitis obliterans organizing pneumonia-like changes) treated with infliximab. Furthermore, we present an overview of cases of inflammatory bowel disease with lung involvement, treated with tumor necrosis factor-α antagonists. In this case, when infliximab was given, a significant resolution of the pulmonary changes was achieved.

Entities:  

Year:  2009        PMID: 21172273     DOI: 10.1016/j.crohns.2009.03.007

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  5 in total

Review 1.  [Pulmonary manifestations of inflammatory bowel disease].

Authors:  O Bachmann; F Länger; J Rademacher
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

2.  Pulmonary involvement in Crohn's disease.

Authors:  Rodolfo Augusto Bacelar de Athayde; Felipe Marques da Costa; Ellen Caroline Toledo do Nascimento; Roberta Karla Barbosa de Sales; Andre Nathan Costa
Journal:  J Bras Pneumol       Date:  2018 Nov-Dec       Impact factor: 2.624

Review 3.  Inflammatory bowel disease and the lung in paediatric patients.

Authors:  Anja Jochmann; Daniel Trachsel; Jürg Hammer
Journal:  Breathe (Sheff)       Date:  2021-03

4.  Inflammatory bowel disease of the lung: The role of infliximab?

Authors:  Adam J Hayek; Timothy P Pfanner; Heath D White
Journal:  Respir Med Case Rep       Date:  2015-05-27

Review 5.  Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature.

Authors:  Lisa Horgan; Siobhain Mulrennan; Lloyd D'Orsogna; Andrew McLean-Tooke
Journal:  BMC Gastroenterol       Date:  2019-11-01       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.